SU2C-funded trial shows immunotherapy reduces soft tissue sarcoma relapse risk by 43% at two years.
Stand Up To Cancer-funded trial finds immunotherapy reduces soft tissue sarcoma relapse risk by 43% at two years. The clinical trial, run by a SU2C Catalyst Research Team, was supported by Merck's Investigator Studies Program and sponsored by Sarcoma Alliance for Research through Collaboration. The research is likely to impact the standard of care for two types of sarcoma and was presented at the 2024 American Society of Clinical Oncology Annual Meeting.
June 03, 2024
3 Articles